Vutrisiran shows potential to become the new standard of care for rare heart disease

Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation

DefiniGEN Ltd., and Atelerix Ltd., today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US.

June 3, 2024

Medicare expects a big spike in spending on Leqembi

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday.

April 15, 2024

New Standard for Unresectable Hepatocellular Carcinoma?

SAN FRANCISCO — After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized

January 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.